Cas:7696-00-6 N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine manufacturer & supplier

Chemical Name:N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine

CAS.NO:7696-00-6

Synonyms:UNII-2879S26V4P;Mitotenaminum;Mitotenamine;Mitotenamine [INN:BAN];Mitotenamina

Molecular Formula:C₁₃H₁₅BrClNS

Molecular Weight:332.68700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:368.5ºC at 760 mmHg

Density:1.445g/cm3

Index of Refraction:1.632

PSA:31.48000

Exact Mass:330.98000

LogP:4.72450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like UNII-2879S26V4P chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Mitotenamina physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Mitotenamine [INN:BAN] Use and application,Mitotenamina technical grade,usp/ep/jp grade.

Related News: He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine manufacturer From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine supplier FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine vendor He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. N-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-N-ethylethanamine factory He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients.